BlackRock Inc. increased its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,165,242 shares of the medical equipment provider’s stock after purchasing an additional 47,673 shares during the quarter. BlackRock Inc. owned 7.02% of ABIOMED worth $1,028,829,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Marathon Capital Management lifted its stake in ABIOMED by 4.0% during the fourth quarter. Marathon Capital Management now owns 780 shares of the medical equipment provider’s stock worth $253,000 after purchasing an additional 30 shares during the last quarter. Kornitzer Capital Management Inc. KS lifted its stake in ABIOMED by 0.5% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 6,930 shares of the medical equipment provider’s stock worth $2,253,000 after purchasing an additional 35 shares during the last quarter. Bbva Compass Bancshares Inc. lifted its stake in ABIOMED by 3.7% in the fourth quarter. Bbva Compass Bancshares Inc. now owns 1,417 shares of the medical equipment provider’s stock valued at $461,000 after buying an additional 50 shares during the last quarter. Cornerstone Advisors Inc. raised its stake in shares of ABIOMED by 304.8% during the fourth quarter. Cornerstone Advisors Inc. now owns 85 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 64 shares in the last quarter. Finally, Shine Investment Advisory Services Inc. raised its stake in shares of ABIOMED by 319.0% during the fourth quarter. Shine Investment Advisory Services Inc. now owns 88 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 87.68% of the company’s stock.
Get ABIOMED alerts:
NASDAQ:ABMD opened at $334.50 on Friday. The stock has a market cap of $15.16 billion, a P/E ratio of 136.53, a PEG ratio of 3.53 and a beta of 0.38. ABIOMED, Inc. has a 52-week low of $258.10 and a 52-week high of $459.75.
ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, January 31st. The medical equipment provider reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.03. The firm had revenue of $200.56 million for the quarter, compared to analyst estimates of $200.60 million. ABIOMED had a return on equity of 20.31% and a net margin of 30.12%. Analysts anticipate that ABIOMED, Inc. will post 3.61 EPS for the current year.
In related news, COO David M. Weber sold 24,000 shares of ABIOMED stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $351.47, for a total value of $8,435,280.00. Following the transaction, the chief operating officer now owns 161,842 shares of the company’s stock, valued at approximately $56,882,607.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Martin P. Sutter sold 5,985 shares of ABIOMED stock in a transaction dated Wednesday, February 6th. The shares were sold at an average price of $349.49, for a total value of $2,091,697.65. Following the transaction, the director now directly owns 212,943 shares in the company, valued at approximately $74,421,449.07. The disclosure for this sale can be found here. Insiders sold a total of 74,928 shares of company stock worth $26,515,812 in the last three months. 3.50% of the stock is currently owned by company insiders.
A number of equities research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of ABIOMED from a “hold” rating to a “buy” rating and set a $370.00 price objective on the stock in a research note on Friday, January 18th. BidaskClub upgraded shares of ABIOMED from a “hold” rating to a “buy” rating in a research note on Friday, December 28th. ValuEngine lowered ABIOMED from a “buy” rating to a “hold” rating in a report on Wednesday. BTIG Research raised ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 target price on the stock in a report on Friday, November 2nd. Finally, Morgan Stanley lowered their target price on ABIOMED from $496.00 to $461.00 and set an “overweight” rating on the stock in a report on Wednesday, January 2nd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. ABIOMED has an average rating of “Buy” and an average price target of $421.00.
ILLEGAL ACTIVITY WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at www.tickerreport.com/banking-finance/4188404/abiomed-inc-abmd-shares-bought-by-blackrock-inc.html.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Recommended Story: What are catch-up contributions?